Price Alert

Jazz Pharmaceuticals (JAZZ)

NASDAQ: JAZZ · Real-Time Price · USD

129.50

1.48 (1.16%)

At close: Sep 05, 2025, 3:59 PM

129.50

0.00%

After-hours: Sep 05, 2025, 04:10 PM EDT

Jazz Pharmaceuticals Statistics

Share Statistics

Jazz Pharmaceuticals has 60.66M shares outstanding. The number of shares has increased by -2.01% in one year.

Shares Outstanding	60.66M
Shares Change (YoY)	-2.01%
Shares Change (QoQ)	-0.36%
Owned by Institutions (%)	95.13%
Shares Floating	57.71M
Failed to Deliver (FTD) Shares	2,017
FTD / Avg. Volume	0.26%

Short Selling Information

The latest short interest is 5.62M, so 9.12% of the outstanding shares have been sold short.

Short Interest	5.62M
Short % of Shares Out	9.12%
Short % of Float	10.51%
Short Ratio (days to cover)	5.54

Valuation Ratios

The PE ratio is 13.6 and the forward PE ratio is 5.96. Jazz Pharmaceuticals's PEG ratio is 0.35.

PE Ratio	13.6
Forward PE	5.96
PS Ratio	1.87
Forward PS	1.8
PB Ratio	1.86
P/FCF Ratio	5.65
PEG Ratio	0.35

Financial Ratio History

Enterprise Valuation

Jazz Pharmaceuticals has an Enterprise Value (EV) of 11.36B.

EV / Sales	2.79
EV / EBITDA	8.3
EV / EBIT	8.14
EV / FCF	8.43

Financial Position

The company has a current ratio of 4.46, with a Debt / Equity ratio of 1.51.

Current Ratio	4.46
Quick Ratio	3.99
Debt / Equity	1.51
Debt / EBITDA	4.05
Debt / FCF	4.57
Interest Coverage	3.01

Financial Efficiency

Return on Equity is 13.68% and Return on Invested Capital is 7.77%.

Return on Equity	13.68%
Return on Assets	4.66%
Return on Invested Capital	7.77%
Revenue Per Employee	$1.45M
Profits Per Employee	$200.04K
Employee Count	2,800
Asset Turnover	0.34
Inventory Turnover	0.93

Taxes

Income Tax	-91.43M
Effective Tax Rate	-19.44%

Stock Price Statistics

The stock price has increased by 20.87% in the last 52 weeks. The beta is 0.24, so Jazz Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.24
52-Week Price Change	20.87%
50-Day Moving Average	116.23
200-Day Moving Average	119.26
Relative Strength Index (RSI)	67.67
Average Volume (20 Days)	769,784

Income Statement

In the last 12 months, Jazz Pharmaceuticals had revenue of 4.07B and earned 560.12M in profits. Earnings per share was 9.06.

Revenue	4.07B
Gross Profit	3.62B
Operating Income	716.63M
Net Income	560.12M
EBITDA	1.52B
EBIT	861.64M
Earnings Per Share (EPS)	9.06

Full Income Statement

Balance Sheet

The company has 2.41B in cash and 6.16B in debt, giving a net cash position of -3.75B.

Cash & Cash Equivalents	2.41B
Total Debt	6.16B
Net Cash	-3.75B
Retained Earnings	1.13B
Total Assets	10.94B
Working Capital	1.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.4B and capital expenditures -48.07M, giving a free cash flow of 1.35B.

Operating Cash Flow	1.4B
Capital Expenditures	-48.07M
Free Cash Flow	1.35B
FCF Per Share	21.8

Full Cash Flow Statement

Margins

Gross margin is 89.05%, with operating and profit margins of 17.61% and 13.77%.

Gross Margin	89.05%
Operating Margin	17.61%
Pretax Margin	11.56%
Profit Margin	13.77%
EBITDA Margin	33.63%
EBIT Margin	17.61%
FCF Margin	33.12%

Dividends & Yields

JAZZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	7.36%
FCF Yield	17.7%

Dividend Details

Analyst Forecast

The average price target for JAZZ is $179, which is 38.2% higher than the current price. The consensus rating is "Buy".

Price Target	$179
Price Target Difference	38.2%
Analyst Consensus	Buy
Analyst Count	13

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$146.59
Lynch Upside	13.2%
Graham Number	116.15
Graham Upside	-10.31%

Scores

Altman Z-Score	1.11
Piotroski F-Score	5